Search alternatives:
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
141
BMISES_Data_Part1.
Published 2025“…BMI was a significant factor in PTB for lower socioeconomic status (LSES) women. …”
-
142
Baseline characteristics of HSES/LSES population.
Published 2025“…BMI was a significant factor in PTB for lower socioeconomic status (LSES) women. …”
-
143
Baseline characteristics of overall population.
Published 2025“…BMI was a significant factor in PTB for lower socioeconomic status (LSES) women. …”
-
144
Diagram of study population.
Published 2025“…BMI was a significant factor in PTB for lower socioeconomic status (LSES) women. …”
-
145
-
146
Test soil parameters.
Published 2025“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”
-
147
Influence of UHMWPE length on swelling pressure.
Published 2025“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”
-
148
UHMWPF parameters.
Published 2025“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”
-
149
Influence of UHMWPE content on swelling pressure.
Published 2025“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”
-
150
Soil partice-size distribution.
Published 2025“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”
-
151
-
152
-
153
-
154
-
155
AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner.
Published 2025“…Scale bars = 100µm <b>(f)</b> Dose-response relationship between AZ10606120 treatments and cell number in U251 cell cultures demonstrating that increasing AZ10606120 concentrations (0-50µM) correlated to decreasing cell number. This relationship was modelled using a non-linear least squares regression model for a sigmoidal curve. …”
-
156
-
157
-
158
-
159
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
160
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”